Skip to Content

ZymoGenetics Filing: Merck Serono Discontinues Atacicept Study

NEW YORK, Sept. 28, 2009--Zymogenetics said in an SEC filing today that "licensee, Merck Serono SA, recently decided to voluntarily discontinue the ongoing studies in multiple sclerosis (MS) for the investigational drug atacicept . This decision was taken based upon a recommendation from an Independent Data Monitoring Committee (the Committee), who determined that the risk/benefit relationship did not justify the continuation of these studies. In one of the studies, the Committee observed an increase in MS disease activity (mean number of relapses and MRI lesions) in the atacicept treatment arms compared to the placebo arm. Two ongoing studies of atacicept, one in rheumatoid arthritis and one in systemic lupus erythematosus, are continuing, as no comparable issues have been identified in these studies."

Below is a link to the filing.

Posted: September 2009